Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.GeoVax Labs has entered into a $10 million common stock purchase agreement with Fusion Capital Fund II.
Subscribe to our email newsletter
The company may sell up to $10 million of its common stock to Fusion Capital from time to time over a 25-month period after the Securities and Exchange Commission has declared effective a registration statement related to the transaction. GeoVax will use the proceeds to further its developmental HIV/AIDS vaccine, expected to enter Phase II human clinical trials later this year.
Under the agreement, the company has the right to sell shares of its common stock to Fusion Capital from time to time in amounts between $80,000 and $1 million, depending on certain conditions, up to $10 million in the aggregate. The purchase price of the shares will be based on the prevailing market prices of the company’s shares at the time of sales without any fixed discount, and the company will control the timing and amount of any sales of shares to Fusion Capital. There are no negative covenants, restrictions on future financings, penalties or liquidated damages in the agreement.
Robert McNally, GeoVax’s president and CEO, said: “This agreement will help us continue to move forward with our AIDS vaccine development efforts.”